Derma Sciences Inc. (NASDAQ:DSCI) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded shares of Derma Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $7.35.
Shares of Derma Sciences (NASDAQ:DSCI) opened at 4.67 on Tuesday. The firm has a 50-day moving average of $4.70 and a 200 day moving average of $4.20. The company’s market capitalization is $132.18 million. Derma Sciences has a 52-week low of $2.85 and a 52-week high of $5.99.
Derma Sciences (NASDAQ:DSCI) last issued its earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.16. The company had revenue of $22.20 million for the quarter, compared to analyst estimates of $22.40 million. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. On average, analysts anticipate that Derma Sciences will post ($0.04) EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Emerald Acquisition Ltd. bought a new stake in shares of Derma Sciences during the second quarter valued at approximately $202,000. Dimensional Fund Advisors LP increased its stake in shares of Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock valued at $207,000 after buying an additional 7,086 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock valued at $364,000 after buying an additional 73,911 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Derma Sciences by 23.3% in the first quarter. Renaissance Technologies LLC now owns 541,800 shares of the company’s stock valued at $1,680,000 after buying an additional 102,500 shares during the period. Hedge funds and other institutional investors own 62.44% of the company’s stock.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.